The present disclosure is related to medicine administration and tracking and, more specifically, to accessory devices, systems, and methods for medicine administration and tracking.
Diabetes mellitus (“diabetes”) is a metabolic disease associated with high blood sugar due to insufficient production or use of insulin by the body. Diabetes affects hundreds of millions of people and is among the leading causes of death globally. Diabetes has been categorized into three types: type 1, type 2, and gestational diabetes. Type 1 diabetes is associated with the body's failure to produce sufficient levels of insulin for cells to uptake glucose. Type 2 diabetes is associated with insulin resistance, in which cells fail to use insulin properly. Gestational diabetes can occur during pregnancy when a pregnant woman develops a high blood glucose level. Gestational diabetes often resolves after pregnancy; however, in some cases, gestational diabetes develops into type 2 diabetes.
Various diseases and medical conditions, such as diabetes, require a user to self-administer doses of medicine. When administering a liquid medicine by injection, for example, the appropriate dose amount is set and then dispensed by the user, e.g., using a syringe, a medicine delivery pen, or a pump. Regardless of the particular device utilized for injecting the liquid medicine, it is important track medicine dosed and facilitate a user's compliance with a dosing regime, particularly for managing lifelong or chronic conditions like diabetes.
Provided in accordance with aspects of the present disclosure is an accessory for use with a medicine delivery device. The accessory includes a body configured to attach to a medicine delivery device and a user interface disposed on the body and configured to communicate information to a user. The user interface includes first and second lights configured to be selectively illuminated and a first symbol associated with the first light. The first light and the first symbol together indicate an action to be performed when the first light is illuminated.
In an aspect of the present disclosure, the first light is a green light and the second light is a red light.
Attorney Docket No. A0005809US01 (2865-32)
In another aspect of the present disclosure, the first light is a green light and the first symbol represents at least a portion of the medicine delivery device such that, when the green light is illuminated, the action to be performed of using the medicine delivery device is indicated.
In still another aspect of the present disclosure, the user interface further includes a second symbol associated with the second light. In such aspects, the second light and the second symbol together provide an indication to the user. More specifically, the second light may be a red light and the second symbol may be a stop symbol such that, when the red light is illuminated, the indication to the user is to stop and not proceed with using the medicine delivery device.
In yet another aspect of the present disclosure, the body is configured to releasably attached to the medicine delivery device. In such aspects, the body may be a cap configured to releasably cover a dispensing end of the medicine delivery device.
In still yet another aspect of the present disclosure, the accessory further includes at least one detector disposed within the body and configured to detect at least one of attachment of the cap with the medicine delivery device or detachment of the cap from the medicine delivery device.
In another aspect of the present disclosure, the user interface further includes a third light configured to be selectively illuminated. In such aspects, the first light may be a green light indicating it is safe to use the medicine delivery device to dose, the second light may be a red light indicating it is not safe to use the medicine delivery device to dose, and/or the third light may be a yellow light indicating the user to proceed with caution.
Another accessory for use with a medicine delivery device in accordance with the present disclosure includes a body configured to attach to a medicine delivery device, an electronics unit disposed within the body, and a user interface disposed on the body in communication with the electronics unit. The electronics unit is configured to at least one of receive or determine, with respect to a prior dose at time t0, a first time t1 after which it is safe to dose and a second time t2 before which it is not safe to dose. The user interface includes a green light, a red light, and a yellow light. The electronics unit is configured to control the user interface to illuminate the red light between time t0 and time t2, extinguish the red light and illuminate the yellow light at time t2, maintain the yellow light from time t2 to time t1, and extinguish the yellow light and illuminate the green light at time t1.
In an aspect of the present disclosure, the electronics unit is further configured to control the user interface to maintain the green light from time t1 until a subsequent dose is logged.
In another aspect of the present disclosure, times to, ti, and t2 are relative times (e.g., where t0=0 or a start of a count-up timer) or clock times (e.g., actual times on a 12 hr or 24 hr clock).
In still another aspect of the present disclosure, the body is a cap configured to releasably cover a dispensing end of the medicine delivery device. In such aspects, at least one detector may be disposed within the body and configured to detect at least one of attachment of the cap with the medicine delivery device or detachment of the cap from the medicine delivery device.
In yet another aspect of the present disclosure, the electronics unit is configured to determine or receive a determination that a dose from the medicine delivery device has occurred based at least upon at least one of an attachment of the cap or a detachment of the cap.
In still yet another aspect of the present disclosure, the determination that a dose from the medicine delivery device has occurred is further based upon which light is illuminated. More specifically, no determination that a dose from the medicine delivery device has occurred may be made despite the at least one of attachment of the cap or detachment of the cap when the red light is illuminated. Alternatively or additionally, the determination that a dose from the medicine delivery device has occurred may be made based upon the at least one of attachment of the cap or detachment of the cap and other criteria when either the green light or the yellow light is illuminated. In aspects, the criteria when the green light is illuminated are different from the criteria when the yellow light is illuminated.
Medicine delivery device 20 is detailed and illustrated herein as a medicine delivery pen, although any other suitable medicine delivery device may be provided such as, for example, a syringe, a pump, etc. Pen 20, described in greater detail below, is operable to select, set, and/or dispense a dose of medicine, e.g., a dose of insulin. Pen 20 may be configured as a disposable device, e.g., wherein pen 20 is discarded once emptied of medicine, or a reusable device configured to enable refilling and/or replacement of a medicine cartridge thereof. Although referred to herein in the singular, it is understood that reference to pen 20 is not limited to single pen 20 but may apply to multiple pens 20 with which accessory device 110 is utilized.
Computing device 30 is detailed and illustrated herein as a smartphone, although any other suitable computing device may be provided such as, for example, a tablet, a wearable computing device (e.g., a smart watch, smart glasses, etc.), a laptop and/or desktop computer, a smart television, a network-based server computer, etc.
Accessory device 110 is detailed herein as a cap for selectively covering a dispensing end of pen 20, although other suitable accessory devices 110 configured, for example, to mechanically engage a body 22 of pen 20, facilitate holding pen 20 on a support surface (e.g., a table), facilitate retaining pen 20 during transport (e.g., in a user's pocket or bag), etc. are also contemplated.
Health management application 40 is paired with accessory device 110, which may be a prescription-only medical device for use with medicine delivery devices, e.g., pen 20, via smartphone 30, although other suitable configurations are also contemplated. In aspects, the pairing of smartphone 30 with accessory device 110 at least partially unlocks health management application 40 to enable the user to utilize some or all features of health management application 40, e.g., according to the user's prescription. Thus, the act of pairing can unlock and enable the functionality of health management application 40 and/or system 10 (including accessory device 110), while health management application 40 (and/or system 10) may provide only limited features in the absence of pairing with accessory device 110.
Health management application 40 of smartphone 30, in aspects, can monitor and/or control functionalities of accessory device 110 and provide a dose calculator module and/or decision support module that can calculate and recommend a dose of medicine for the user to administer using pen 20. Health management application 40 provides a user interface, on the user interface of smartphone 30, to allow a user to manage health-related data. For example, health management application 40 can be configured to control some functionalities of accessory device 110 and/or to provide an interactive user interface to allow a user to manage settings of accessory device 110 and/or settings for smartphone 30 that can affect the functionality of system 10. Smartphone 30 can additionally or alternatively be used to obtain, process, and/or display contextual data that can be used to relate to the health condition of the user, including the condition for which pen 20 is used to treat. For example, smartphone 30 may be operable to track the location of the user; physical activity of the user including step count, movement distance and/or intensity, estimated calories burned, and/or activity duration; and/or interaction pattern of the user with smartphone 30. In aspects, health management application 40 can aggregate and process the contextual data to generate decision support outputs, e.g., on the user interface and/or on accessory device 110, to guide and aid the user in monitoring their condition, using pen 20, and/or managing their behavior to promote treatment and better health outcomes.
In aspects, system 10 further includes a data processing system 50 in communication with accessory device 110 and/or smartphone 30. Data processing system 50 can include one or more computing devices in a computer system and/or communication network accessible via the internet, e.g., including servers and/or databases in the cloud. System 10 can additionally or alternatively include sensor device 60 to monitor one or more health metrics and/or physiological parameters of the user. Examples of health metric and physiological parameter data monitored by sensor device 60 include analytes (e.g., glucose), heart rate, blood pressure, user movement, temperature, etc. Sensor device 60 may be a wearable sensor device such as a continuous glucose monitor (CGM) to obtain transcutaneous or blood glucose measurements that are processed to produce continuous glucose values. For example, the CGM can include a glucose processing module implemented on a stand-alone display device and/or implemented on smartphone 30, which processes, stores, and displays the continuous glucose values for the user. Such continuous glucose values can be utilized by health management application 40, for example, for displaying health data, in dose calculation and/or decision support, etc.
Smartphone 30 can receive dose and related information (e.g., which can include time information, dose setting information, and/or dose dispensing information) via manual entry by the user and/or automatically from a connected tracking device (within or associated with pen 20, accessory device 110, and/or other connected device(s)). Upon receipt of the dose and related information, smartphone 30 stores the information in memory 33, e.g., which can be included among a list of doses or dosing events. In aspects, via the user interface associated with health management application 40, smartphone 30 allows the user to browse a list of previous doses, to view an estimate of current medicine active in the user's body (medicine on board, e.g., insulin on board) based on calculations performed by health management application 40, and/or to utilize a dose calculation module to assist the user regarding dose setting information on the size of the next dose(s) to be delivered. For example, the user may enter carbohydrates to be eaten and current blood sugar (which alternatively may be obtained directly from sensor device 60 (
Referring to
In aspects, in order to operate pen 20, the user first sets e.g., dials, a dose using a dose knob 26a of dose setting mechanism 25. For example, the dose may be adjusted up or down to achieve a desired dose amount prior to administration of the dose by rotating dose knob 26a in an appropriate direction. A dose indicator window 26d through body 22 is provided to enable a user to view the units set via dose knob 26a. Once the appropriate dose has been set, the user applies a force against a dose dispensing button 26b of dose dispensing mechanism 24 to begin dispensing. More specifically, to begin dispensing, the user presses against the portion of dose dispensing button 26b that protrudes from body 22 of pen 20 to thereby drive a driving element 26c, e.g., a drive screw 26c, of dose dispensing mechanism 24 against an abutment, e.g., piston 23b, of medicine cartridge 23 to dispense an amount of medicine from cartridge 23 through needle 29 into the user in accordance with the dose amount set by dose setting mechanism 25, e.g., dose knob 26a, during setting. Needle 29 may be integrated with pen 20 and/or cartridge 23 or may be removable and replaceable from pen 20 and/or cartridge 23.
Dose dispensing mechanism 24 of pen 20 can include a manually powered mechanism (user powered and/or mechanically biased), a motorized mechanism, or an assisted mechanism (e.g., a mechanism that operates partly on manual power and partly on motorized power). Regardless of the particular configuration of the dose dispensing mechanism 24, as noted above, when a force (e.g., a manual force, electrically-powered motor force, or combinations thereof) is applied to drive screw 26c of dose dispensing mechanism 24, drive screw 26c turn provides a force to urge medicine from medicine cartridge 23 to deliver the set or dialed dose. In aspects, dose dispensing mechanism 24 can be operated such that rotation and/or translation of the driving element, e.g., drive screw 26c, is facilitated by a variable tension spring or a variable speed motor to inject the dose over a specific time frame (e.g., 1 s, 5 s, etc.) to help reduce the pain of dosing and/or for other purposes.
Medicine cartridge 23 includes a vial body 23a defining an interior volume configured to retain a volume of medicine, e.g., insulin, therein, and a piston 23b sealingly and slidingly disposed within vial body 23a such that displacement of piston 23b within vial body 23a towards the dispensing end of vial body 23a forces medicine from the interior volume through dispensing opening 23c of cartridge 23 and needle 29 for injection into the user.
The rotation of the dose knob 26a during actuation drives (direct or indirect) rotation of drive screw 26c which rides within a nut (not explicitly shown) which is fixed to body 22 of pen 20. In this manner, rotation of drive screw 26c also results in translation of drive screw 26c (due to the pitched threading of drive screw 26c ) towards medicine cartridge 23 to thereby drive piston 23b through vial body 23a to expel medicine from medicine cartridge 23 for injection into the user. The extent to which dose knob 26a extends from body 22 of pen 20 prior to actuation (which corresponds to the selected dose to be injected) defines the maximum amount of rotation of dose knob 26a and, thus, drive screw 26c during actuation; as such, the amount of medicine expelled from medicine cartridge 23 during actuation cannot exceed the selected dose amount.
Turning to
Cap 110 further includes an electronics unit 120 that includes a detector (e.g., detection switch 122), a battery 124, a printed circuit board assembly (PCBA) 126, and a user interface 130. PCBA 126 may include a processor, a real-time clock, a storage module, and/or a communications module for wireless data transfer (e.g., via Bluetooth, WiFi, cellular network, and/or other suitable wireless communication protocol) to and/or from smartphone 30 (
A cover 150 of body 112 encloses (and, in aspects, seals) the cavity and, thus, electronics unit 120 therein. Where a seal is provided, it may be hermetic to inhibit damage to electronics 120 from exposure to fluids, debris, etc. The output device(s) producing user interface 130 may form part of cover 150 to enable output (e.g., visual, audible, or other sensory output) from user interface 130, and/or cover 150 may include openings or other features to enable output of the output devices(s) producing user interface 130 on cover 150. The output device(s) producing user interface 130 may include a display screen, one or more LED's or other visual indicators, a speaker or other audio output device, a haptic feedback device, and/or other suitable user interface features configured to communicate information to a user.
When pen 20 is inserted into cap 110, pen 20 urges slider 118 to translate against the bias of spring 138 and interact with a deflectable arm 137 associated with detection switch 122 that extends into the travel path of slider 118. More specifically, the deflectable arm 137 of detection switch 122 may be biased to extend into the travel path (in the absence of slider 118) and to deflect out of the travel path in response to contact by and urging from slider 118 as slider 118 is translated within housing 116, e.g., under urging from the insertion of pen 20 into cap 110. Sufficient deflection of deflectable arm 137 closes (or opens) detection switch 122 such that a signal is detected by electronics unit 120 indicating that pen 20 has been inserted into cap 110. On the other hand, when pen 20 is removed from cap 110, slider 118 translates, under the bias of spring 138 back to its initial position, spaced-apart from deflectable arm 137. As such, deflectable arm 137 is returned to its initial, biased position extending into the travel path. As deflectable arm 137 is returned to this initial, biased position, detection switch 122 is opened (or closed) such that a signal is detected by electronics unit 120 indicating that pen 20 has been removed from cap 110.
Additional aspects and features of cap 110, configured for use in whole or in part in accordance with the aspects and features of the present disclosure (in whole or in part) can be found in U.S. Patent Application Pub. No. 2020/0327973, filed on Apr. 13, 2020 and titled “Intelligent Accessories for Medicine Dispensing Device,” the entire contents of which are hereby incorporated herein by reference.
Continuing with reference to
Referring to
Non-contact sensor 722, further still, may be an accelerometer or other suitable vibration sensor configured to sense vibrations associated with movement of slider 118 and/or movement of pen 20 (FIG.4) during insertion and engagement of pen 20 (
Other suitable locations for sensor 722 are also contemplated depending upon a particular purpose such as, for example, to sense movement and/or other properties of spring 738 rather than slider 118. In aspects wherein spring 738 is a coil spring, for example, sensor 722 may be configured to sense movement, e.g., approximation or spacing, of the rungs of spring 738, e.g., optically, or may be configured to sense an amount of compression of spring 738, e.g., electrically based on a change in capacitance of spring 738 as it is compressed or extended. As movement of spring 738 is related to whether pen 20 (
With reference to
Continuing with reference to
Turning to
In aspects, the lights 1032, 1034, 1036 may be red, yellow, and green lights, respectively, arranged in that order (or red and green where only lights 1032, 1036 are provided). Although the red/yellow/green and red/green light schemes are generally known and utilized for various purposes, it has been found that in certain situations, such as with respect to indicating whether it is safe to dose, the red/yellow/green and red/green light schemes may be confusing, even with certain symbology associated therewith. For example, where a green light is illuminated, the user may be confused as to whether the green light is an indication that the user is in compliance and, thus, does not need to dose, or whether the indication is telling the user that it is safe to dose. Likewise, where a red light is illuminated, the user may likewise be confused as to whether the red light is indicating that the user is not in compliance and needs to dose, or whether the indication is telling the user that it is not safe to dose.
To obviate the above confusion, lights 1032, 1034, 1036 (or at least lights 1032, 1036 (whether only lights 1032, 1036 are provided or all three lights 1032, 1034, 1036 are provided)) and associated symbology 1033, 1035, 1037, respectively, are provided in a manner that clarifies the action to be taken. For example, symbol 1037 is positioned adjacent green light 1036 (or otherwise associated therewith such as, for example, where symbol 1037 is overlayed or otherwise positioned relative to green light 1036 such that symbol 1037 is illuminated when green light 1037 is illuminated). Symbol 1037 indicates the action to be taken; that is, the action that it is safe to proceed when the green light 1036 is illuminated. Symbol 1037 may be an image or other representation of a needle (as shown), a syringe, an injection pen, an amount of medicine, or other suitable symbol indictive of the delivery of medicine to the user. Symbol 1033 is positioned adjacent (or otherwise associated with) red light 1032 and indicates the action to be taken; that is, “stop” or “do not proceed” when the red light 1032 is illuminated. Symbol 1033 may be an image or other representation to “stop” such as, for example, a stop hand signal (as shown), a stop sign, or other suitable symbol indicating to the user to stop or take no action because it is not safe to dose. In configurations where yellow light 1034 is provided, symbol 1035 is positioned adjacent (or otherwise associated with) yellow light 1034 and provides an indication of caution, e.g., via a caution sign or other suitable symbol, thus indicating the user to proceed with caution because it is not recommended to dose but may acceptable.
Control of, e.g., selective illumination of, lights 1032, 1034, 1036 may be provided by electronics unit 120 (
With additional reference to
In addition to the “safe to dose” time “t1,” there is a time “t2” before which it is not safe to dose, thus defining a second period of time “P2,” wherein P2=t2−t0. As red light 1032 and corresponding symbol 1033 indicate to the user that it is not safe to dose, red light 1032 is illuminated at time “t0” and remains illuminated throughout period “P2” until time “t2.” Period of time “P2” may be pre-determined or dynamically determined. In aspects, if cap 110 is removed from pen 20 (
In aspects where no yellow light 1034 is provided, t1=t2and P1=P2. However, it has been found that there may be a time period “P3” defined between times “t2” and “t1” wherein, while it is not recommended to dose, it may be acceptable to dose in certain circumstances, for example, where the user is not able to dose for an extended length of time after expiration of time period “P1,” e.g., due to a social commitment, work commitment, personal reason, or any other reason. Time period “P3” may be pre-determined or dynamically determined, and is defined in relation to “P1” and “P2” according to the equation P1=P2+P3.
In aspects where time period “P3” is utilized, red light 1032 is extinguished at time “t2” and yellow light 1034 is illuminated. Yellow light 1034, indicating that the user should proceed with caution because it is not recommended to dose but may be acceptable, remains illuminated for the duration of time period “P3” until time “t1,” after which yellow light 1034 is extinguished and green light 1036 is illuminated until the next dose is logged. With yellow light 1034 illuminated, a dose is logged when cap 110 is removed from pen 20 (
Although the above control implementation of lights 1032, 1034, 1036 describes the illumination and extinguishing of lights 1032, 1034, 1036 in an activated condition, it is noted that the control implementation may not be activated at all times but, rather, may have a dormant condition. That is, in the dormant condition, all lights may be extinguished, e.g., to conserve battery and inhibit distraction. For example, the above control implementation may be activated from the dormant condition when motion is sensed, indicating that pen 20 (
In aspects, rather than providing user interface 130 on cap 110, user interface 130 may be provided on body 22 of pen 20 (see
The various aspects and features disclosed herein may be combined in different combinations than the combinations specifically presented in the description and accompanying drawings. It should also be understood that, depending on the example, certain acts or events of any of the processes or methods described herein may be performed in a different sequence, may be added, merged, or left out altogether (e.g., all described acts or events may not be necessary to carry out the techniques). In addition, while certain aspects of this disclosure are described as being performed by a single module or unit for purposes of clarity, it should be understood that the techniques of this disclosure may be performed by a combination of units or modules associated with, for example, a medical device.
In one or more examples, the described functional and/or operational aspects may be implemented in hardware, software, firmware, or any combination thereof. If implemented in software, the functions may be stored as one or more instructions or code on a computer-readable medium and executed by a hardware-based processing unit. Computer-readable media may include non-transitory computer-readable media, which corresponds to a tangible medium such as data storage media (e.g., RAM, ROM, EEPROM, flash memory, or any other medium that can be used to store desired program code in the form of instructions or data structures and that can be accessed by a computer).
Instructions may be executed by one or more processors, such as one or more digital signal processors (DSPs), general purpose microprocessors, application specific integrated circuits (ASICs), field programmable logic arrays (FPGAs), or other equivalent integrated or discrete logic circuitry. Accordingly, the term “processor” or “processing unit” as used herein may refer to any of the foregoing structure or any other physical structure suitable for implementation of the described techniques. Also, the techniques could be fully implemented in one or more circuits or logic elements.
While several aspects of the present disclosure have been detailed above and are shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description and accompanying drawings should not be construed as limiting, but merely as exemplifications of particular aspects. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.